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Abstract  26 
Atypical/Nor98 Scrapie (AS) is a prion disease of small ruminants. Currently there are no 27 
efficient measures to control this form of prion disease and, importantly, the zoonotic 28 
potential and the risk that AS might represent for other farmed animal species remains largely 29 
unknown. In this study, we investigated the capacity of AS to propagate in bovine PrP 30 
transgenic mice. Unexpectedly, the transmission of AS isolates originating from five different 31 
European countries to bovine PrP mice resulted in the propagation of the classical BSE (c-32 
BSE) agent. Detection of prion seeding activity in vitro by protein misfolding cyclic 33 
amplification (PMCA) demonstrated that low levels of the c-BSE agent were present in the 34 
original AS isolates. C-BSE prion seeding activity was also detected in brain tissue of ovine 35 
PrP mice inoculated with limiting dilutions (end-point titration) of ovine AS isolates. These 36 
results are consistent with the emergence and replication of c-BSE prions during the in-vivo 37 
propagation of AS isolates in the natural host. These data also indicate that c-BSE prions, a 38 
known zoonotic in humans, can emerge as a dominant prion strain during passage of AS 39 
between different species. These findings provide an unprecedented insight into the evolution 40 
of mammalian prion strain properties triggered by intra- and inter-species passage. From a 41 
public health perspective, the presence of c-BSE in AS isolates suggest that cattle exposure to 42 
small ruminant tissues and products could lead to new occurrences of c-BSE.  43 
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Significance Statement 49 
The origin of transmissible BSE in cattle remains unestablished. Sheep scrapie is a potential 50 
source of this known zoonotic. Here we investigated the capacity of sheep scrapie to 51 
propagate in bovine PrP transgenic mice. Unexpectedly, transmission of atypical but not 52 
classical scrapie in bovine PrP mice resulted in propagation of classical BSE prions. Detection 53 
of prion seeding activity by in vitro protein misfolding cyclic amplification demonstrated BSE 54 
prions in the original atypical scrapie isolates. BSE prion seeding activity was also detected in 55 
ovine PrP mice inoculated with limiting dilutions of atypical scrapie. Our data demonstrate 56 
that classical BSE prions can emerge during intra- and inter-species passage of atypical 57 




Transmissible spongiform encephalopathies (TSEs), or prion diseases, are fatal 61 
neurodegenerative disorders that affect a large spectrum of mammalian species. These 62 
conditions include scrapie in small ruminants, classical bovine spongiform encephalopathy (c-63 
BSE) in cattle and sporadic Creutzfeldt-Jakob disease (sCJD) or variant CJD (vCJD) in 64 
humans.  65 
 66 
The fundamental event in prion propagation is the conversion of the normal cellular prion 67 
protein (PrP
C
) into an abnormal disease-associated isoform (PrP
Sc
) in tissues of infected 68 
individuals. PrP
C
 is completely degraded by digestion with proteinase K (PK) whereas PrP
Sc 
is 69 
N-terminally truncated resulting in a PK resistant core termed PrP
res 
(1). According to the 70 
prion concept, PrP
Sc 
is the principal, if not sole component of the transmissible prion agent (2) 71 
and PrP
res
 is a disease marker for prion diseases (1, 3). Particular biochemical properties of 72 
PrP
Sc
, such as detergent solubility, PK resistance and electromobility evidenced by western 73 
blot can be used to distinguish between different prion agents or strains (4, 5). 74 
 75 
Intra-species transmission of prion disease between individuals is typically quite efficient. In 76 
contrast, inter-species transmission of prions can be unpredictable with apparent failure of 77 
disease transmission on many occasions. In other cases, clinical prion disease may not be 78 
evident but rather there is the presence of subclinical infection (6). When inter-species prion 79 
transmission does occur, the propagating agent can remain identical to the original prion 80 
strain, or can display different biological properties compared to the original inoculum (7, 8). 81 
This complex set of outcomes for inter-species prion challenge are collectively referred to as 82 
the transmission barrier phenomenon. 83 
 84 
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After identification of the gene encoding PrP it was soon discovered that differences in amino 85 
acid sequence between host PrP
C
 and donor PrP
Sc
 constitutes the principal determinant of the 86 
transmission barrier. For example, the resistance of wild-type mice to clinical prion disease 87 
induced by hamster scrapie is abrogated by transgenic expression of hamster PrP
C
 in mice (9, 88 
10). As a consequence, mice genetically engineered to express particular species forms of PrP 89 
sequence, in the absence of endogenous mouse PrP, have emerged as relevant models to 90 
experimentally characterize the outcome of prion strain transmission between species (11). It 91 
is also now well established that strain properties have a significant impact on the ability of 92 
prions to cross the species barrier. For instance, human vCJD can be transmitted readily to 93 
conventional mice but it is extremely difficult for sCJD to propagate in the same mouse lines 94 
(12, 13). Furthermore, the amino acid sequence of PrP
Sc
 influences the efficacy of inter-95 
species prion transmissions since studies in human PrP transgenic mouse models indicate that 96 
the human species barrier is more permeable to sheep-passaged BSE compared to its cattle 97 
counterpart (14).  98 
 99 
From a public health perspective, the transmission barrier phenomenon and its capacity to 100 
limit the inter-species propagation of prion disease has long been considered as an effective 101 
protection of humans against animal TSEs (15). However, in 1996, the new human prion 102 
disease vCJD was observed in UK individuals. Multiple lines of evidence indicated that vCJD 103 
was the likely consequence of dietary exposure of humans to the agent responsible for c-BSE 104 
in cattle, an epizootic prion disease that has spread in bovine hosts through the recycling of 105 
prion-contaminated animal carcasses in the animal food chain (16). Since the emergence of 106 
vCJD, considerable efforts have been deployed to characterize not only the zoonotic potential 107 
of animal prions but also their capacity to propagate in farmed animal species. 108 
 109 
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Atypical/Nor98 scrapie (AS) probably represents the largest geographically spread known 110 
animal prion disease. Since its original discovery in 1998 in Norway, AS has been identified 111 
in most EU member states, in Asia and in North and South America (17). AS has also been 112 
detected in Australia and New Zealand, two countries that were believed to be free of animal 113 
TSEs (18, 19). Retrospective studies carried out in archived animal tissues identified an AS 114 
case in a sheep that died in 1972 in the UK demonstrating that the disease has been present in 115 
small ruminant populations for many decades (20).  116 
 117 
Bioassay in ovine PrP transgenic mice provided evidence that AS comprised a single prion 118 
strain (21-23). The AS prion strain was associated with a multi-band PrP
res
 signature that 119 
contrasted with those normally observed in small ruminant TSE cases (24). Since there is no 120 
statistical difference in the apparent prevalence of atypical scrapie between sheep flocks in 121 
general and those flocks where a positive case had been identified, atypical scrapie is 122 
considered by many as a non-contagious prion disease that arises sporadically in sheep and 123 
goats (25). However, atypical scrapie can be experimentally transmitted via the oral route in 124 
small ruminants, resulting in a similar clinico-pathological phenotype to that observed in 125 
natural cases (26). Consequently, the origin of atypical scrapie (spontaneous disorder versus 126 
acquired disease) remains an open question.  127 
 128 
In this study we used mice transgenic for bovine PrP (tgBov mouse line) to characterize the 129 
capacity of sheep AS isolates to cross the bovine transmission barrier. Unexpectedly, the TSE 130 
agent that propagated in tgBov mice was indistinguishable from the prion strain that was 131 
responsible for the c-BSE epizootic in cattle. In addition, our sensitive detection of c-BSE by 132 
in vitro PMCA methodology indicated that this bovine prion strain was present as a minor 133 
prion strain in the original sheep AS isolates, and that AS prion strain replication in an ovine 134 
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PrP host was accompanied by the generation of c-BSE prions. Collectively, these data provide 135 
compelling evidence for the emergence and the propagation of zoonotic mammalian prions 136 
during intra- and inter-host transmission of the AS prion strain.  137 
138 
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Results  139 
A panel of 8 atypical scrapie (AS) cases collected from sheep and goats in five different 140 
European countries was obtained (Table1). All of the AS isolates displayed a multi-band 141 
abnormal PrP (PrP
res
) western blot profile that was considered to be specific for small 142 
ruminant AS (SI appendix Figure S1). This panel of AS isolates was transmitted to the VRQ 143 
ovine PrP transgenic mice (tg338). The transmission properties such as incubation period (SI 144 
appendix Table S1), vacuolar lesion profile (Figure 1a) and PrP
res
 western blot profile in the 145 
brain (SI appendix Figure S1), of the propagated AS isolates observed after two or three 146 
iterative passages in tg338 were similar and were the same as that previously reported for AS 147 
passage in tg338 mice (21-23).  148 
 149 
The panel of 8 AS isolates was individually serially transmitted (2 or 3 iterative passages) in 150 
bovine PrP transgenic mice (tgBov) (Table 1). On first passage, signs of clinical prion disease 151 
were observed in a low proportion of inoculated tgBov mice. PrP
res
 was detected by western 152 
blot in the brains of clinically affected mice and in some mice that displayed no apparent 153 
clinical signs of prion disease when euthanised at the end of their life expectancy. No PrP
res
 154 
accumulation was observed in tgBov mice after inoculation with several of the AS isolates 155 
(AS 2, AS 3, AS 5, AS 6 and AS 7), as was the case with classical scrapie PS42 (Table 1). 156 
 157 
Second passage of the AS isolates in tgBov mice was performed using either first passage 158 
PrP
res
-positive brains or pooled PrP
res
-negative brains as inoculum. During this process, 7 out 159 
of the 8 AS isolates caused the occurrence of clinical prion disease in a proportion of animals 160 
in each group inoculated. On third passage (available for AS 1, 2, 3, 4 and 7) 100% attack 161 
rates and mean incubation periods that ranged between 235 and 286 dpi were recorded (Table 162 
1). 163 
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At each passage stage, a three band PrP
res
 western blot profile characterised by a prominent 164 
di-glycosylated PrP band was observed in the brains of the clinically-positive tgBov mice 165 
(Figure 1b). Strikingly, the lesion profile (Figure 1a), the PrP
res
 western blot profile (Figure 166 
1b) and the histopathological lesions (Figure 1c) in the brains of AS inoculated tgBov mice 167 
were identical to those observed for transmission of c-BSE (sheep or cattle origin) to tgBov 168 
mice. Importantly, the inoculation of one classical scrapie isolate (PS42) to the same mouse 169 
models resulted in the occurrence of a 100% attack rate for prion disease with a short 170 
incubation period in tg338 mice (SI appendix Table S1), but no clinical disease or PrP
res
 171 
accumulation in the brains of tgBov (Table 1). 172 
 173 
In order to further characterize the nature of the TSE agent that propagated in tgBov mice 174 
inoculated with the AS isolates, prions obtained after second passage (isolate AS 2) or third 175 
passage (isolate AS 3) in this mouse line were transmitted (two iterative passages) to VRQ 176 
(tg338) and ARQ (tgARQ) ovine PrP transgenic mice (Table 2). The incubation periods 177 
(Table 2 and SI appendix Table S1), the lesion profile (Figure 2a) and the PrP
res
 western blot 178 
profile in the brain (Figure 2b) of tg338 mice inoculated with tgBov-adapted AS isolates 179 
clearly differed from those observed in the same mouse line inoculated with the original AS 180 
isolates.  181 
No PrP
res
 deposition could be detected in the spleen of tg338 mice inoculated with the original 182 
AS isolates (Figure 3a). Conversely, transmission in tg338 of tgBov-adapted AS isolates was 183 
associated with a PrP
res
 accumulation in the spleen as was transmission of ovine and cattle c-184 
BSE (Figure 3a). PrP
res
 WB profile in the spleen of tg338 mice that were inoculated with c-185 
BSE and AS isolates passaged in tgBov were identical (Figure 3b). 186 
Transmission of tgBov-adapted AS isolates in both tg338 and tgARQ mice resulted in prion 187 
incubation periods (Table 2), brain vacuolar lesion profiles (Figure 2a), PrP
res
 western blot 188 
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profile patterns (Figure 2b) and PrP
res
 distribution patterns in the brain (Figure 3a) that were 189 
similar to c-BSE passaged in tg338 and tgARQ mice. Collectively these results demonstrate 190 
beyond reasonable doubt that our transmission of AS in a bovine PrP host resulted in the 191 
propagation of the c-BSE agent. Since the bioassays reported here were performed in three 192 
independent institutes (located in France and Spain) that used inoculum prepared by five 193 
distinct laboratories, we exclude the possibility of a cross contamination of the original AS 194 
isolates by the c-BSE agent. 195 
 196 
Two hypotheses could explain the emergence of the c-BSE agent in tgBov mice after their 197 
inoculation with AS isolates. Firstly, c-BSE prions could be present at a low level in the 198 
original AS isolates. The high sensitivity of tgBov mice for detection of the c-BSE agent 199 
could allow this potentially low level of bovine prions to be identified during passage of the 200 
original AS isolates in the bovine PrP host. Alternatively, the occurrence of c-BSE in AS-201 
inoculated tgBov mice could result from a mutation of AS strain properties triggered by 202 
passage across the bovine transmission barrier for this particular ovine prion strain.  203 
 204 
In order to explore the origin of the c-BSE agent observed in tgBov mice inoculated with AS, 205 
we employed in vitro protein misfolding cyclic amplification (PMCA), a methodology that 206 
mimics prion replication in vitro, but in an accelerated form, allowing amplification of minute 207 
amounts of PrP
Sc
 and prion infectivity (27). In PMCA, a PrP
C
-containing substrate is 208 
combined with a seed that contains PrP
Sc
. Following repeated cycles of incubation and 209 




PMCA has been previously reported to amplify the c-BSE agent with a great efficacy using 212 
either tgARQ or tgBov mouse brain homogenate as substrate (28). Using this protocol two 213 
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(tgARQ substrate) or three (tgBov substrate) amplification rounds were sufficient to reach the 214 
detection limit for c-BSE prion seeding activity (SI appendix Figure S2). The level of prion 215 
infectivity and prion seeding activity of a reference sheep-passaged c-BSE isolate were end-216 
point titrated by both bioassay in tgBov mice and PMCA, respectively (SI appendix Table 217 
S2). The infectious prion titer of the sheep-passaged c-BSE isolate was ≈10
7.2
 LD50/g IC in 218 
tgBov mice. The prion seeding titer (SA50) was estimated to be ≈10
11.1
 SA50/g using tgARQ 219 
mouse tissue as substrate and 10
11.05
 SA50/g using tgBov mouse tissue as substrate. 220 
Considering the fact that mice were inoculated using 20µL of sample and the PMCA reactions 221 
were seeded using 5µL of the same sample, the PMCA can be considered to be about 1500 222 
fold more sensitive than the bioassay in tgBov. This also means that 1 c-BSE LD50 in tgBov 223 
mice corresponds to ≈1500 SA50 assessed by PMCA.  224 
 225 
In addition to its high sensitivity, in vitro PMCA can reproduce, at least partly, the 226 
transmission barrier phenomenon observed during the in vivo prion bioassay (29). Therefore, 227 
amplification of prion seeding activity in AS isolates by PMCA using tgBov mouse tissue as 228 
substrate offered an opportunity to characterize the potential impact of the bovine 229 
transmission barrier on AS strain properties.   230 
 231 
The AS isolates that were originally transmitted to tgBov mice (except AS8) and 18 additional 232 
AS isolates (originating from Norway, France, and Portugal) were subjected to PMCA (Table 233 
4). Each AS isolate was used to seed reactions containing either bovine PrP or ovine ARQ PrP 234 
substrate (10 to 18 replicates per substrate). After amplification, PrP
res
 was detected by 235 
western blot in a low proportion of the reactions seeded with 19 out of the 25 AS isolates for 236 
tgBov and tgARQ combined (Table 3). In most instances, a similar proportion of PrP
res
-237 
positive PMCA reactions were observed when either bovine PrP or ovine ARQ PrP was used 238 
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as substrate. However, in some cases (n=3), a low number of PrP
res
-positive reactions were 239 
observed when bovine PrP was used as substrate (in the case of AS 10) or when ovine ARQ 240 
PrP was used as substrate (in the case of AS 9, and AS 25). Whatever combination of AS 241 
isolate and substrate PrP used, the PrP
res
 western blot profile in PMCA-positive reaction 242 
products and its reactivity with 12B2 antibody were indistinguishable from those observed for 243 
PMCA reaction products seeded with authentic ovine c-BSE prions (Figure 4). No PrP
res
 was 244 
observed in PMCA reactions that were unseeded (n=120) or in those reactions seeded (n=60) 245 
with prion-free sheep brain homogenate (representative samples shown in Figure 4). It should 246 
be noted that the PrP amino sequence was 100% homologous between certain AS isolates (AS 247 
5, AS 26) and the ovine PrP substrate (tgARQ) used in PMCA reactions. Therefore, in vitro 248 
amplification of c-BSE prions in PMCA reactions seeded with these AS isolates using ovine 249 
ARQ PrP as substrate cannot be a consequence of mutation of prion strain properties triggered 250 
by a transmission barrier. 251 
 252 
Taken together, the tgBov mouse bioassay and PMCA results strongly support the view that a 253 
low level of c-BSE prions was initially present in at least 21 out of the 26 AS isolates tested.  254 
 255 
To further clarify the origin of the c-BSE agent detected in AS isolates, two of these isolates 256 
(AS 25 and AS 26) were end-point titrated in tg338 mice (1/10 dilution series, 6 to 7 tg338 257 
mice inoculated per dilution). For both isolates, the last positive transmissions were observed 258 
in mice that received a 10
-6
 log10 dilution of the original 10% w/vol brain material (SI 259 
appendix Table S3). The brains of these end-point titration tg338 mice were subsequently 260 
subjected to PMCA. Irrespective of the substrate used for PMCA, either bovine or ovine ARQ 261 
PrP, PrP
res
 was observed in a similar proportion of the PMCA reactions seeded with either the 262 
original AS isolates, or AS isolates passaged in tg338 mice (Table 4). The PrP
res
 western blot 263 
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profile observed in all the PMCA-positive reactions was identical to that seen in reactions 264 
seeded with authentic c-BSE prions (Figure 5). PMCA reactions seeded with brain 265 
homogenate prepared from age matched non-inoculated tg338 mice remained PrP
res
 negative 266 
(Table 4 and Figure 5).  267 
 268 
Considering the level of c-BSE seeding activity originally present in isolates AS 25 and AS 269 
26 (less than 100 SA50/mL, Table 5), there is an extremely low level of probability that one of 270 
the six tg338 mice inoculated with 20µL of a 10
-6
 diluted AS isolate (<2 10
-6
 SA50 per dose of 271 
inoculum) could be exposed to 1 infectious dose of c-BSE agent (1 c-BSE LD50 is ≈1500 272 
SA50). Consequently, the presence of c-BSE prion seeding activity in the brains of tg338 mice 273 
inoculated with a 10
-6
 log10 dilution of original AS isolate implies that a low titer of c-BSE 274 
prions was generated during the propagation of ovine AS prions in a host that expressed ovine 275 





The mechanism(s) that lead to an alteration in the phenotype of prion strains as these 280 
transmissible entities undergo transmission between different host species remain uncertain. 281 





, together with prion strain identity are principal determinants of the 283 
transmission barrier (9, 10). Based on the concept that conformation of PrP
Sc
 284 
molecules/aggregates encode prion strain information (2, 4, 5, 30, 31), at least two non-285 
exclusive hypotheses, ‘deformed templating’ (32, 33) and the ‘conformational selection 286 
model’ (32-35) have been proposed to explain the mutation of prion strains. 287 
 288 
The ‘deformed templating’ hypothesis postulates that a prion strain replicates as a clone of 289 
PrP
Sc
 molecules/aggregates. When confronted by a transmission barrier that does not allow 290 
clonal prion replication, the propagation process is modified so that ‘altered’ PrP
Sc
 structural 291 
variants are generated in an attempt to convert the new host PrP
C
. While the majority of these 292 
presumably fail to replicate efficiently in the new host, variants eventually emerge that are 293 
successful and adapt to the new PrP environment through multiple trial-and-error replication 294 
events. In this ‘deformed templating’ model, confrontation of the transmission barrier serves 295 
as the triggering event that initiates the generation of new prion variant(s) and as a filter for 296 
their selection (35). 297 
 298 
The ‘conformational selection model’ proposes that a prion strain naturally propagates in its 299 
host as an ensemble of PrP
Sc
 conformers dominated by a stable energetically favourable 300 
conformation responsible for the observed prion strain phenotype. Furthermore, this model 301 
predicts that the number of stable PrP
Sc
 conformers is limited for each PrP amino acid 302 
sequence, which would explain the existence of a finite number of stable prion strains that can 303 
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propagate in a given species. It is further proposed that during transmission of a prion strain to 304 
a new host, one of the less dominant PrP
Sc
 conformers of those present in the ensemble is 305 
selected with a resultant change, or mutation, in the properties of the newly propagating prion 306 
strain. In the ‘conformational selection model’, the transmission barrier acts simply as a 307 
selective filter for new prion variants, and ease of permeation of the barrier results from the 308 
extent of overlap of PrP
Sc
 conformers that exist between the interacting species (32, 33).  309 
 310 
Our data reported here showed that c-BSE prions are present as a minor variant in natural 311 
isolates of ovine AS. In addition, transmission of ovine AS to bovine PrP mice demonstrated 312 
that c-BSE can emerge during these transmissions as the dominant prion strain. These results 313 
provide a cogent argument in favour of the ‘conformational selection model’ as the 314 
mechanism for prion strain mutation during inter-species prion transmission. This would be 315 
expected to occur by selection of a pre-existing PrP
Sc
 variant in AS isolates, one best suited to 316 
the new replicative environment. Within this conceptual framework, the occurrence of prion 317 
strain mutation is dependent upon the particular repertoire of PrP
Sc
 variants associated with 318 
distinct prion strains. This notion is supported by our observation that c-BSE prions emerged 319 
during serial transmission of ovine AS in tgBov mice but not from serial passage of classical 320 
scrapie in the same mouse line (Table 1 and Cassard et al (15)).  321 
 322 
The diversity of prion strains that exist in small ruminants remains undefined although it is 323 
established that at least 5 different natural ovine prion strains exist including AS (6, 36-39). 324 
According to the ‘conformational selection model’, each of these different ovine prion strains 325 
is associated with a unique and stable PrP
Sc
 conformer and a distinct set of minor variants. 326 
The tgBov mouse line has previously been reported to support the propagation of a variety of 327 
natural ovine prions, of which several displayed significantly shorter incubation periods than 328 
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c-BSE (15). Strikingly, in our experiments the diversity of prion variants in the AS isolates 329 
(seven different cases) revealed by the serial passage in tgBov was restricted to the c-BSE 330 
agent (Table 1). This consistent emergence of a single prion strain argues against the view that 331 
AS prion replication in sheep can randomly generate all the existing stable PrP
Sc
 variants 332 
associated with a particular ovine PrP
C
 amino acid sequence. Instead, our data support the 333 
view that individual prion strains are associated with a restricted repertoire of stable PrP
Sc
 334 
variants in a given host.  Whether AS is unique in its ability to generate c-BSE prion particles 335 
during its replication process remains to be established. 336 
 337 
Classical BSE was first recognized in 1984-85 as a novel prion disease affecting cattle in the 338 
UK (40). Epidemiological data clearly established that the number of cases of c-BSE was 339 
amplified by the recycling of infected animal carcasses into cattle feed in the form of meat 340 
and bone meal (MBM) (41). Since bovine prion disease had not been recognized in cattle 341 
prior to the c-BSE epizootic and the disease is apparently non-contagious between cattle, 342 
several hypotheses were proposed to explain its emergence. These range from the spontaneous 343 
occurrence of c-BSE in cattle to the passage and adaptation of a prion originating from 344 
another species (42, 43). Our studies here that show the presence of c-BSE prions in AS 345 
isolates combined with the demonstrated presence of AS in the UK long before the 346 
appearance of the c-BSE epizootic in cattle suggests that the recycling of AS cases in MBM 347 
might be a source of bovine prion disease (20).  In addition to its potential role in the initial 348 
emergence of c-BSE in cattle, the presence of c-BSE prions in natural cases of AS has current 349 
and direct implications for both the continued risk of this ovine prion disease to other farmed 350 
animals and for human exposure risks. The distribution of AS cases are widespread across the 351 
world (17-19). A recent retrospective analysis of surveillance data collected over a period 352 
exceeding 10 years in the European Union (EU) concluded that the prevalence of detected AS 353 
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cases has remained relatively stable in the different member states with between 2-6 positive 354 
cases per 10,000 tested animals per year. This implies that a substantial number of AS-355 
infected animals could enter either the animal or human food chain each year (44, 45), and 356 
each case represents a potential source of exposure to the c-BSE agent for farmed animals 357 
(MBM derived from rendered small ruminants) and human consumers (consumption of 358 
healthy slaughtered animals), respectively. The epidemiological features of AS within the EU 359 
is likely to reflect the situation of the disease in other countries that breed and maintain small 360 
ruminants.  361 
 362 
In Europe, the c-BSE crisis and the emergence of vCJD resulted in the implementation of a 363 
strong and coherent policy (EU regulation 999/2001) aimed at control and eradication of this 364 
animal prion disease. The total feed ban on the use of MBM in animal feed and the systematic 365 
retrieval from the food chain of ruminant tissues that have the potential to contain high levels 366 
of prion infectivity, so called Specified Risk Material (SRM) measures, were instrumental for 367 
control of c-BSE in cattle and preventing dietary human exposure to these bovine prions (46, 368 
47). As a side effect, these measures also strongly limited the exposure of farmed animals and 369 
human consumers to the other TSE agents circulating in farmed animal species, including AS.  370 
 371 
With the decline of the c-BSE epizootic in cattle and the combined increase in pressure from 372 
industry, EU authorities have begun to consider discontinuing certain TSE control measures. 373 
The abrogation of the SRM measures for small ruminants and the partial re-authorization of 374 
the use of processed animal protein, formerly known as MBM in animal feed are part of the 375 
EU authorities’ agenda. Our observation of the presence of the c-BSE agent in AS-infected 376 
small ruminants suggest that modification of the TSE control measures could result in an 377 
increased risk of exposure to c-BSE prions for both animals and humans. Whether or not this 378 
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exposure will result in further c-BSE transmission in cattle and/or humans remains an open 379 





Ethics Statement 384 
All animal experiments were performed in compliance with institutional and French national 385 
guidelines and in accordance with the European Directives 86/609/EEC and 2010/63/EU. In 386 
France, the animal experiments that are part of this study (national registration 01734.01) 387 
were approved by the local ENVT ethics committee. Experiments developed in CISA-INIA 388 
(Madrid, Spain) were approved by the Committee on the Ethics of Animal Experiments of the 389 
Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria and the General 390 
Directorate of the Madrid Community Government (permit numbers: CEEA 2009/004 and 391 
PROEX 228-16). Mouse inoculations were performed under anaesthesia (isofluorane).  392 
Experiments  developed in IRTA-CReSA (Barcelona, Catalonia) involving animals were 393 
approved by the animal experimentation ethics committee of the Autonomous University of 394 
Barcelona (Reference number: 585-3487) in agreement with Article 28, sections a), b), c) and 395 
d) of the “Real Decreto 214/1997 de 30 de Julio” and the European Directive 86/609/CEE and 396 
the European council Guidelines included in the European Convention for the Protection of 397 
Vertebrate Animals used for Experimental and Other Scientific Purposes.  398 
Mice that displayed clinical signs were anesthetized with isofluorane before sacrifice using 399 
CO2 inhalation. 400 
 401 
Atypical/Nor98 scrapie cases and control sheep  402 
Natural atypical scrapie (AS) cases identified through active or passive surveillance programs 403 
were selected according to their geographical origin (France, Spain, Italy, Norway and 404 
Portugal) and PRNP genotypes (SI appendix Table S1 and Table 1). These cases have been 405 
originally classified as AS by TSE national reference laboratories in each country. All the 406 
cases corresponded to sheep except the AS 7 case (goat). 407 
 20 
 408 
In all cases, PrP genotype was checked by sequencing the Exon 3 of the PRNP gene as 409 
previously described (48). The polymorphisms at codons 136 (A/V), 154 (H/R) and 171 410 
(R/Q/H), which have been demonstrated to strongly influence the susceptibility to TSE in 411 
sheep are indicated (49). Additionally, the presence of a phenylalanine at codon 141 (F/L), 412 
which has been shown to impact on the susceptibility to atypical/Nor98 scrapie, are also 413 
indicated (Table 1 and 4) (23, 48). Brain material collected in TSE-free Poll-Dorset sheep 414 
(APHA, Weybridge, UK) was used as control (50).  415 
 416 
c-BSE isolates 417 
Cattle and ovine classical BSE (c-BSE) isolates were used as control. The cattle c-BSE isolate 418 
was a natural case originating from France. This isolate was used in previous studies aimed at 419 
the characterization of c-BSE strain properties though transmission to mice over-expressing 420 
the PrP sequence of various host species (51). The  ovine c-BSE isolate was obtained by the 421 
intracerebral inoculation of the same cattle c-BSE isolate in ARQ/ARQ TSE free sheep (first 422 
passage) as described in Andreoletti et al 2004 (50).  423 
 424 
Mouse bioassays 425 
Bioassays were carried out using mice expressing bovine PrP (tgBov /tg110) (52, 53) and/or 426 
mice expressing ovine ARQ (tgARQ) (54) or VRQ (tg338) PrP (55).  427 
 428 
Groups of six- to ten-week-old female mice (n ≥6) were anesthetized and inoculated with 429 
20µL of a 10% tissue homogenate in the right parietal lobe using a 25-gauge disposable 430 
hypodermic needle. Mice were observed daily and their neurological status was assessed 431 
weekly. When clinically progressive TSE disease was evident, the animals were euthanized 432 
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and their brains harvested. Half of the brain was fixed by immersion in 10% formol saline and 433 
the other half was frozen at -20ºC. Tissues from animals found dead were frozen (no formalin 434 
fixation). In animals where no clinical signs were observed, mice were killed at the end of 435 
their natural life-span (650 to 750 days). In those cases, incubation periods reported in the 436 
table as >650 dpi, corresponded to the survival time observed in at least three out of the six 437 
mice.  438 
 439 
PMCA Amplification 440 
Brains from tgBov, tgARQ and tg338 were used to prepare the PMCA substrates. PMCA was 441 
performed as previously described (28, 56). Briefly PMCA reactions (50µL final volume) 442 
were seeded with 5µL of sample to be tested. PMCA reactions were then subjected to 3 443 
amplification rounds each comprising 96 cycles (10s sonication-14 minutes and 50 seconds 444 
incubation at 39.5°C) in a Qsonica700. After each round, reaction products (1 volume) were 445 
mixed with fresh substrate (9 volumes) to seed the following round. The PMCA reaction 446 
products were analysed by western blot for the presence of PK-resistant PrP. Each WB line 447 
was loaded with the equivalent of 20 µL of PK digested PMCA product. Each PMCA run 448 
included a reference ovine BSE sample (10% brain homogenate) as a control for the 449 
amplification efficiency. Unseeded controls (2 unseeded controls for 8 seeded reactions) were 450 
also included in each run. 451 
 452 
Western blot detection of abnormal PrP 453 
PK-resistant abnormal PrP (PrP
res
) extraction and western blot were performed as previously 454 
described (57). Immunodetection was performed using two different PrP-specific monoclonal 455 
antibodies: Sha31 (1 µg/ml) (58), and 12B2 (4 µg/ml) (59), which recognize the amino acid 456 




Paraffin embedded tissue blot  460 
Paraffin embedded brain tissue from inoculated mice was analysed as previously described 461 
(61-63). 462 
 463 
Lesion profiling and abnormal PrP immunohistochemistry. 464 
Vacuolar brain lesion profiles were established following the method described by Fraser et al 465 
(64). In situ PrP
Sc
 immune-labelling was performed as previously described (63), using 6H4 466 
anti PrP antibody (epitope: 147DYEDRYYRE155 of the bovine PrP- concentyrtation 3µg/mL).  467 
 468 
Infectious and seeding activity titer estimates 469 
A series of 1/10 dilutions of a reference 10% w/vol brain stem from an ovine-BSE 470 
(ARQ/ARQ) isolate and two AS isolates (AS 25 and AS 26) were prepared. Successive 1/10 471 
dilutions of brain homogenate were inoculated intra-cerebrally (20µl) into tgBov or tg338 472 
mice (n=6 per inoculum). Dilutions of the same c-BSE isolate were used to seed PMCA 473 
reactions that used brain tissue from either bovine PrP (tgBov mice) or ovine ARQ PrP 474 
(tgARQ mice) as substrate. Twelve individual replicates of each sample dilution were tested. 475 
Reactions were then subjected to three amplification rounds. PMCA reaction products (third 476 
amplification round) were analysed by western blot for the presence of PrP
res
. The titer of 477 
prion seeding activity was estimated by the Spearman-Kärber’s method (65). 478 
 479 
For AS and AS passaged in tg338 isolates (10% brain homogenate), 1/50 diluted material was 480 
used to seed twelve individual reactions (tgBov or tgARQ substrates). After three 481 
amplification rounds the number of PrP
res
 western blot positive reactions / total number of 482 
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reactions was established. These ratios were used to estimate seeding activity titers (SA/µL of 483 
10% brain homogenate) by the limiting dilution titration method (application of Poisson’s 484 
probabilistic model) described by Brown et al (66) or by the Spearman-Kärber’s method. 485 
According to Fisher et al (67) and as previously used for prion infectivity comparisons (68) 486 
one SA50 was considered to be equivalent to 0.693 SA. 487 
 488 
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 490 
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Legends of Figures 660 
 661 
Figure 1: Brain lesion profile and PrP
res
 western blot profiles in tgBov and tg338 mice 662 
inoculated with atypical/Nor98 scrapie (AS) or c-BSE  663 
 664 
Groups of mice (n≥6) that express either ovine VRQ PrP (tg338 mice) or bovine PrP (tgBov 665 
mice) were intra-cerebrally challenged with atypical scrapie isolates (AS) or an ovine classical 666 
BSE isolate (c-BSE). 667 
(a) After two or three iterative passages in each mouse line a standard lesion profile was 668 
established by scoring the vacuolar changes observed in pre-defined brain areas. In c-BSE 669 
graphs : ovine c-BSE, : cattle c-BSE. In AS graphs:  : AS 1, : AS 2, : AS 3). 670 
(b) The accumulation of PK-resistant PrP (PrP
res
) in the brain of tgBov mice was established 671 
by western blot using anti PrP monoclonal antibodies Sha31 (epitope 145-YEDRYYRE-152) 672 
and/or 12B2 (epitope 89-WGQGG-93). The same western blot PrP
res
 control (classical scrapie 673 
isolate) was used on all the gels labelled as WB control. Cattle c-BSE and an ovine c-BSE 674 
(original isolate and isolate passaged in tgBov) were included as controls. 675 
(c) Vacuolar lesions (thalamus level, conventional histology; hematoxylin-eosin, bar: 25 µm) 676 
and abnormal PrP deposition (Mesencephalon: tegmentum, immunohistochemistry using 6H4 677 
anti PrP antibody, epitope 147-DYEDRYYRE-155, bar: 50µm) in tgBov mice inoculated with 678 
AS3 and cattle BSE. 679 
 680 
 681 
Figure 2: Brain lesion profile and PrP
res
 Western blot in the brain of tgARQ and tg338 682 
mice inoculated with AS scrapie adapted in tgBov 683 
 684 
Groups of mice (n≥6) that express ovine VRQ PrP (tg338 mice) or ovine ARQ PrP (tgARQ 685 
mice) were intra-cerebrally challenged with atypical scrapie isolates (AS) or an ovine c-BSE 686 
isolate that had previously been adapted (2 iterative passages) in tgBov mice.  687 
(a) After two iterative passages in each mouse line a standard lesion profile was established 688 
by scoring the vacuolar changes observed in pre-defined brain areas. In AS graphs : AS 2, 689 
: AS 3. 690 
(b) The western blot profile of PK resistant PrP (PrP
res
) in the original AS isolates and in the 691 
brain of inoculated mice was established by western blot using anti PrP monoclonal antibody 692 
Sha31 (epitope 145-YEDRYYRE-152). The same western blot PrP
res
 control (classical 693 
scrapie isolate) was used on all the gels labelled as WB control. 694 
 695 
Figure 3: Brain and spleen PrP
res
 accumulation in tg338 mice inoculated with AS scrapie 696 
adapted in tgBov 697 
 698 
Groups of mice (n≥6) that express ovine VRQ PrP (tg338 mice) were intra-cerebrally 699 
challenged with atypical scrapie isolates (AS) and AS that had previously been adapted (2 700 
iterative passages) in tgBov mice. In parallel, cattle c-BSE isolate and ovine BSE isolate 701 
(adapted in tg Bov) were transmitted (2 iterative passages) in tg338 mice. 702 
(a) In tg338 mice (2
nd
 passage) the PrP
res
 distribution pattern in the brain (thalamic coronal 703 
section: bar: 160 µm) and in the spleen (bar: 100 µm) was established by paraffin embedded 704 
tissue blot using anti PrP monoclonal antibody Sha31 (epitope 145-YEDRYYRE-152). 705 
(b) The western blot profile of PK resistant PrP (PrP
res
) in the spleen of tg338 mice (2
nd
 706 
passage) inoculated with AS isolates, AS isolates passaged in tgBov and c-BSE (cattle and 707 






 detection in PMCA reactions seeded with atypical/Nor98 scrapie 711 
isolates. 712 
 713 
Protein misfolding cyclic amplification (PMCA) reactions were seeded with Atypical/Nor98 714 
scrapie (AS) isolates (1/50 diluted 10% brain homogenate) that had been identified in five 715 
European countries (see Table 3). PMCA reactions seeded with brain homogenate from a 716 
TSE-free sheep (originating from New Zealand) and unseeded PMCA reactions were included 717 
as specificity controls. PMCA substrate consisted of brain homogenate from either bovine PrP 718 
(tgBov) or ovine PrP (tgARQ) mice. PMCA reactions were subjected to three (tgARQ 719 
substrate) or four (tgBov substrate) amplification rounds each comprising 96 cycles (10s 720 
sonication-14 minutes and 50 seconds incubation at 39.5°C) in a Qsonica700. The PMCA 721 
reactions were analysed by western blot for the presence of abnormal PK-resistant PrP (PrP
res
) 722 
using anti PrP monoclonal antibodies Sha31 (epitope 145-YEDRYYRE-152) and/or 12B2 723 
(epitope 89-WGQGG-93). Each western blot included a classical scrapie isolate (labelled as 724 
WB control) and an ovine c-BSE isolate as controls. 725 
 726 
Figure 5: PMCA seeding activity detection in two bioassay end-point titrated 727 
Atypical/Nor98 isolates  728 
 729 
Two atypical/Nor98 isolates AS 25 and AS 26 (Table 3) were end-point titrated in tg338 mice 730 
(1/10 dilution series, 6 tg338 mice per dilution). For both isolates, the last positive 731 
transmissions were observed in mice that received a 10
-6
 dilution of the original 10% w/vol 732 
brain material (SI appendix Table S3). The original AS isolates and the brains of clinically 733 
affected mice inoculated with neat and 10
-6
 diluted isolates were used to seed PMCA reactions 734 
that either used tgARQ or tgBov as substrate. PMCA reactions seeded with age matched 735 
inoculated tg338 mice and unseeded reactions were included as specificity controls. Reactions 736 
were subjected to three (tgARQ substrate) or four (tgBov substrate) amplification rounds each 737 
comprising 96 cycles (10s sonication-14 minutes and 50 seconds incubation at 39.5°C) in a 738 
Qsonica700. The PMCA reactions were analysed by western blot for the presence of 739 
abnormal PK resistant PrP (PrP
res
) using the Sha31 (epitope 145-YEDRYYRE-152) and/or 740 
the 12B2 (89-WGQGG-93) anti PrP antibodies. Each western blot included a classical scrapie 741 
isolate (labelled as WB control) and an ovine c-BSE isolate as controls. 742 
 743 
 744 
Table 1: Inoculation of atypical scrapie isolates in bovine PrP (tgBov) expressing mice  
Isolates  TgBov 
    1st passage  2nd passage  3rd passage 











            
AS 1 Fr ARQ*/ARQ  1/6 533  3/5 317±63  7/7 235±16 
            
AS 2 Sp ARR/ARQ  0/6 >650  7/9 354±26  5/5 273±5 
            
AS 3 Sp ARQ/ARH  0/6 >650  2/11 504, 525‡  12/12 269±13 
            
AS 4 Nor ARQ*/ARQ*  3/4 395± 44  6/6 230±17   6/6 271±18 
      
AS 5 Sp ARQ/ARQ  0/6 >650  0/4 >650  NA  
      
AS 6 Sp ARQ/ARH  0/6 >650  1/4 >650‡   NA  
            
AS 7† It ARQ/AHQ   0/6 >650  1/7 424  6/6 286±14 
            
AS 8 Po ARQ/ARQ  1/5 439  5/5 297±14  6/6 250±4 
      
PS42 Fr VRQ/VRQ  0/6 >650  0/6 >650  0/6 >650 
      
Ovine c-
BSE Fr ARQ/ARQ  6/6 254±19  6/6 234±12  6/6 232±6 
            
Cattle c-
BSE Fr -  6/6 295±12  6/6 265±35  6/6 243±7 
      
Transgenic mice that express the bovine PrP (tgBov) were inoculated intra-cerebrally (6 to 12 mice, 20µL per 
mouse) with 8 sheep or goat (†) atypical scrapie (AS) isolates originating from five different countries; France 
(Fr), Spain (Sp), Norway (Nor), Italy (It) or Portugal (Po). The AS affected animals displayed a different PRNP 
genotype at codons 136, 154 and 171. Some also displayed a F/L dimorphism at codon 141 (*). Cattle classical 
BSE (c-BSE), ovine c-BSE (first passage of cattle c-BSE in an ARQ/ARQ sheep by the intracerebral route) and 
classical scrapie (PS42) isolates were inoculated in the same mouse model. After first and second passage, 
clinically affected or asymptomatic mice that had lived for more than 500 days post inoculation were pooled and 
used for subsequent passage in the same line. Mice were considered positive when abnormal PrP deposition was 
detected in the brain. (‡) indicate abnormal PrP positive and found dead animals (without symptoms). Incubation 
periods (in days) are shown as mean±SD except when less than 50% of the mice were found to be positive. In 
that case the incubation periods of the positive mice are individually presented. NA: not available. Cattle c-BSE 
transmission in tgBov data were already reported in Torres et al 2014 (51) 
  
Table 2: Inoculation of atypical scrapie adapted in tgBov and c-BSE isolates in ovine PrP 
expressing mouse models (tg338 and tgARQ) 
   Tg338  TgARQ 
Isolates  1st passage  2nd passage  1st passage  2nd passage 















              
AS 2 2
nd pass in 
TgBov  6/6
‡ >650  6/6 617±75  6/6 350±9  6/6 260±3 
       
AS 3 3
rd pass in 
TgBov   6/6
‡ >650  6/6 672±83  6/6 354±21  6/6 257±2 
              
Ovine c-
BSE 
2nd pass in 
TgBov  6/6
‡ >750  6/6 653±32  6/6 270±12  6/6 259±4 
       
Cattle c-
BSE cattle  6/6
‡ >700  6/6 682±52  6/6 321±16  6/6 263±7 
              
 
Transgenic mice that express the VRQ (tg338) or ARQ (tgARQ) variants of ovine PrP were inoculated intra-
cerebrally (6 mice, 20µL per mouse) with atypical scrapie isolates or ovine c-BSE isolate that had previously 
been adapted in tgBov (2 iterative passages). Cattle BSE was also included as control. After first passage, 
clinically affected or asymptomatic mice that had lived for more than 500 days post inoculation were pooled and 
used for second passage in the same line. Mice were considered positive when abnormal PrP deposition was 
detected in the brain. (‡) indicate abnormal PrP positive and found dead animals (without symptoms). Incubation 
periods (in days) are shown as mean±SD.  
 
  
Table 3: Protein Misfolding Cyclic Amplification seeding activity in atypical scrapie isolates 
Isolates  PMCA positive reactions 
Identifiant Origin Genotype   TgBov substrate  
TgARQ 
substrate 
       
AS 1 Fr ARQ*/ARQ  3/12  5/12 
AS 2 Sp ARR/ARQ  2/12  3/12 
AS 3 Sp ARQ/ARH  3/12  4/18 
AS 4 No ARQ*/AFRQ  12/12  9/12 
AS 5 Sp ARQ/ARQ  4/12  3/12 
AS 6 Sp ARQ/ARH  5/12  1/12 
AS 7 It ARQ/AHQ  1/12  2/12 
AS 8 Po ARQ/ARQ  ND  ND 
       
AS 9 Nor ARR/ARQ 0/12  2/10 
AS 10  ARQ*/AHQ  1/12  0/10 
AS 11  AHQ/ARQ  3/12  7/12 
AS 12  ARR/ARQ  0/12  0/12 
AS 13  ARR/AHQ  0/12  0/12 
AS 14  ARQ/AHQ  1/12  1/12 
AS 15  ARR/ARR  3/12  1/12 
AS 16  ARR/AHQ  1/12  3/10 
AS 17  ARQ*/AHQ  1/12  1/10 
AS 18  ARQ*/AHQ  0/12  0/10 
       
AS 19 Po ARR/ARR 0/12  0/12 
AS 20  ARR/AHQ  3/12  1/12 
AS 21  ARR/ARR  0/12  0/10 
AS 22  ARQ*/AHQ  0/12  0/12 
AS 23  ARQ*/ARQ  1/12  1/12 
AS 24  ARQ*/ARQ  2/12  4/12 
      
AS 25 Fr AHQ/AHQ  0/12  1/12 
AS 26  ARQ/ARQ  1/12  1/12 
       
TSE free sheep  ARQ/ARQ  0/12  0/12 
       
Unseeded  -  0/120  0/120 
       
 
Twenty-six AS scrapie cases (1/50 diluted 10% brain homogenates) originating from five different countries 
(France (Fr), Spain (Sp), Italy (It), Portugal (Po) and Norway (Nor)) were used to seed PMCA reactions (5 µl of 
seed per reaction). The AS affected animals displayed different Prnp genotypes at codons 136, 154 and 171. 
Some also displayed a F/L dimorphism at codon 141 (*).  
Two different PMCA substrates were used. The first one was prepared using brains from transgenic mice over-
expressing the ARQ variant of the sheep prion protein (tgARQ). The second was prepared using brains from 
transgenic mice over-expressing the bovine prion protein (tgBov). For each isolate and substrate ten to eighteen 
individual replicates were tested. Reactions were subjected to 3 amplification rounds. After each round reaction 
products (1 volume) were mixed with fresh substrate (9 volumes) to seed the following round. PMCA reaction 
products (third amplification round) were analysed by western blot for the presence of PrPres. The number of 
PrPres western blot positive reactions / total number of reactions are reported. Unseeded reactions and reactions 
seeded with brain homogenate prepared from a TSE free sheep were included as specificity controls. ND: not 
done. 
Table 4: PMCA seeding activity in atypical scrapie passaged in tg338 
PMCA seeds PrP
res positive 
PMCA reactions  
Seeding activity  
(SA50/mL) 




substrate   
TgARQ  
substrate 
          
AS 25 Sheep   0/12 1/12  0 (0-101.86)*  101.40
 1st passage in tg338 (neat) Mouse 1  2/12 1/12  101.72  10
1.40
 2nd passage in tg338 (neat) Mouse 1  2/12 1/12  101.72  101.40
 End-point titration in tg338 (10-6 dilution) Mouse 1  2/12 3/12  
101.72  101.92 
  Mouse 2  1/12 3/12  101.40  101.92 
  Mouse 3  2/12 2/12  101.72  101.72 
          
AS 26 Sheep   1/12 1/12  101.40  101.40 
 1st passage in tg338 (neat) Mouse 1  2/12 0/12  101.72  0 (0-101.86) * 
 2nd passage in tg338 (neat) Mouse 1  2/12 0/12  101.72  0 (0-101.86) * 
 End-point titration in tg338 (10-6 dilution) Mouse 1  2/12 1/12  10
1.72  10
1.40
  Mouse 2  1/12 1/12  101.40  101.40
          
 Non inoculated tg338  Mouse 1  0/12 0/12  -  - 
  Mouse 2  0/12 0/12 - -
  Mouse 3  0/12 0/12  -  - 
          
Two sheep atypical scrapie (AS) isolates were selected. The 10% w/vol brain homogenates were inoculated into 
tg338 mice (2 iterative passages). Groups of 6 tg338 mice were inoculated intra-cerebrally with 20µL of serial 
ten-fold dilutions of the same homogenates. Transmission was observed in 3 (AS 25) and 2 (AS 26) mice 
inoculated with 10-6 brain homogenate. No transmission was observed at lower dilutions. PMCA reactions (12 
replicates) were seeded with 1/50 diluted brain homogenate (10% w/vol) from (i) the original sheep, (ii) the 
second passage tg338 mice (pool of brains) and (iii) individual brain from positive tg338 in the end-point 
titration experiment. Brain homogenates (10% w/vol) from age matched, non-inoculated tg338 mice were also 
used as seeds (1/50 diluted). Two different PMCA substrates were used. The first one was prepared using brains 
from transgenic mice over-expressing the ARQ variant of the sheep prion protein. The second was prepared 
using brains from transgenic mice over-expressing the bovine prion protein (tgBov). Reactions were subjected to 
up to 4 amplification rounds. After each round reaction products (1 volume) were mixed with fresh substrate (9 
volumes) to seed the following round. PMCA reaction products were analysed by western blot for the presence 
of PrPres. The number of PrPres western blot positive reactions / total number of reactions are reported. Seeding 
activity titers were estimated using the Spearman Karber’s limiting dilution titration method (most likely value) 
or when no positive reaction was observed, by the Poisson’s probabilistic model (*: most likely value and IC 
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Abstract  26 
Atypical/Nor98 Scrapie (AS) is a prion disease of small ruminants. Currently there are no 27 
efficient measures to control this form of prion disease and, importantly, the zoonotic 28 
potential and the risk that AS might represent for other farmed animal species remains largely 29 
unknown. In this study, we investigated the capacity of AS to propagate in bovine PrP 30 
transgenic mice. Unexpectedly, the transmission of AS isolates originating from five different 31 
European countries to bovine PrP mice resulted in the propagation of the classical BSE (c-32 
BSE) agent. Detection of prion seeding activity in vitro by protein misfolding cyclic 33 
amplification (PMCA) demonstrated that low levels of the c-BSE agent were present in the 34 
original AS isolates. C-BSE prion seeding activity was also detected in brain tissue of ovine 35 
PrP mice inoculated with limiting dilutions (end-point titration) of ovine AS isolates. These 36 
results are consistent with the emergence and replication of c-BSE prions during the in-vivo 37 
propagation of AS isolates in the natural host. These data also indicate that c-BSE prions, a 38 
known zoonotic in humans, can emerge as a dominant prion strain during passage of AS 39 
between different species. These findings provide an unprecedented insight into the evolution 40 
of mammalian prion strain properties triggered by intra- and inter-species passage. From a 41 
public health perspective, the presence of c-BSE in AS isolates suggest that cattle exposure to 42 
small ruminant tissues and products could lead to new occurrences of c-BSE.  43 




  48 
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Significance Statement 49 
The origin of transmissible BSE in cattle remains unestablished. Sheep scrapie is a potential 50 
source of this known zoonotic. Here we investigated the capacity of sheep scrapie to 51 
propagate in bovine PrP transgenic mice. Unexpectedly, transmission of atypical but not 52 
classical scrapie in bovine PrP mice resulted in propagation of classical BSE prions. Detection 53 
of prion seeding activity by in vitro protein misfolding cyclic amplification demonstrated BSE 54 
prions in the original atypical scrapie isolates. BSE prion seeding activity was also detected in 55 
ovine PrP mice inoculated with limiting dilutions of atypical scrapie. Our data demonstrate 56 
that classical BSE prions can emerge during intra- and inter-species passage of atypical 57 




Transmissible spongiform encephalopathies (TSEs), or prion diseases, are fatal 61 
neurodegenerative disorders that affect a large spectrum of mammalian species. These 62 
conditions include scrapie in small ruminants, classical bovine spongiform encephalopathy (c-63 
BSE) in cattle and sporadic Creutzfeldt-Jakob disease (sCJD) or variant CJD (vCJD) in 64 
humans.  65 
 66 
The fundamental event in prion propagation is the conversion of the normal cellular prion 67 
protein (PrP
C
) into an abnormal disease-associated isoform (PrP
Sc
) in tissues of infected 68 
individuals. PrP
C
 is completely degraded by digestion with proteinase K (PK) whereas PrP
Sc 
is 69 
N-terminally truncated resulting in a PK resistant core termed PrP
res 
(1). According to the 70 
prion concept, PrP
Sc 
is the principal, if not sole component of the transmissible prion agent (2) 71 
and PrP
res
 is a disease marker for prion diseases (1, 3). Particular biochemical properties of 72 
PrP
Sc
, such as detergent solubility, PK resistance and electromobility evidenced by western 73 
blot can be used to distinguish between different prion agents or strains (4, 5). 74 
 75 
Intra-species transmission of prion disease between individuals is typically quite efficient. In 76 
contrast, inter-species transmission of prions can be unpredictable with apparent failure of 77 
disease transmission on many occasions. In other cases, clinical prion disease may not be 78 
evident but rather there is the presence of subclinical infection (6). When inter-species prion 79 
transmission does occur, the propagating agent can remain identical to the original prion 80 
strain, or can display different biological properties compared to the original inoculum (7, 8). 81 
This complex set of outcomes for inter-species prion challenge are collectively referred to as 82 
the transmission barrier phenomenon. 83 
 84 
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After identification of the gene encoding PrP it was soon discovered that differences in amino 85 
acid sequence between host PrP
C
 and donor PrP
Sc
 constitutes the principal determinant of the 86 
transmission barrier. For example, the resistance of wild-type mice to clinical prion disease 87 
induced by hamster scrapie is abrogated by transgenic expression of hamster PrP
C
 in mice (9, 88 
10). As a consequence, mice genetically engineered to express particular species forms of PrP 89 
sequence, in the absence of endogenous mouse PrP, have emerged as relevant models to 90 
experimentally characterize the outcome of prion strain transmission between species (11). It 91 
is also now well established that strain properties have a significant impact on the ability of 92 
prions to cross the species barrier. For instance, human vCJD can be transmitted readily to 93 
conventional mice but it is extremely difficult for sCJD to propagate in the same mouse lines 94 
(12, 13). Furthermore, the amino acid sequence of PrP
Sc
 influences the efficacy of inter-95 
species prion transmissions since studies in human PrP transgenic mouse models indicate that 96 
the human species barrier is more permeable to sheep-passaged BSE compared to its cattle 97 
counterpart (14).  98 
 99 
From a public health perspective, the transmission barrier phenomenon and its capacity to 100 
limit the inter-species propagation of prion disease has long been considered as an effective 101 
protection of humans against animal TSEs (15). However, in 1996, the new human prion 102 
disease vCJD was observed in UK individuals. Multiple lines of evidence indicated that vCJD 103 
was the likely consequence of dietary exposure of humans to the agent responsible for c-BSE 104 
in cattle, an epizootic prion disease that has spread in bovine hosts through the recycling of 105 
prion-contaminated animal carcasses in the animal food chain (16). Since the emergence of 106 
vCJD, considerable efforts have been deployed to characterize not only the zoonotic potential 107 
of animal prions but also their capacity to propagate in farmed animal species. 108 
 109 
 6 
Atypical/Nor98 scrapie (AS) probably represents the largest geographically spread known 110 
animal prion disease. Since its original discovery in 1998 in Norway, AS has been identified 111 
in most EU member states, in Asia and in North and South America (17). AS has also been 112 
detected in Australia and New Zealand, two countries that were believed to be free of animal 113 
TSEs (18, 19). Retrospective studies carried out in archived animal tissues identified an AS 114 
case in a sheep that died in 1972 in the UK demonstrating that the disease has been present in 115 
small ruminant populations for many decades (20).  116 
 117 
Bioassay in ovine PrP transgenic mice provided evidence that AS comprised a single prion 118 
strain (21-23). The AS prion strain was associated with a multi-band PrP
res
 signature that 119 
contrasted with those normally observed in small ruminant TSE cases (24). Since there is no 120 
statistical difference in the apparent prevalence of atypical scrapie between sheep flocks in 121 
general and those flocks where a positive case had been identified, atypical scrapie is 122 
considered by many as a non-contagious prion disease that arises sporadically in sheep and 123 
goats (25). However, atypical scrapie can be experimentally transmitted via the oral route in 124 
small ruminants, resulting in a similar clinico-pathological phenotype to that observed in 125 
natural cases (26). Consequently, the origin of atypical scrapie (spontaneous disorder versus 126 
acquired disease) remains an open question.  127 
 128 
In this study we used mice transgenic for bovine PrP (tgBov mouse line) to characterize the 129 
capacity of sheep AS isolates to cross the bovine transmission barrier. Unexpectedly, the TSE 130 
agent that propagated in tgBov mice was indistinguishable from the prion strain that was 131 
responsible for the c-BSE epizootic in cattle. In addition, our sensitive detection of c-BSE by 132 
in vitro PMCA methodology indicated that this bovine prion strain was present as a minor 133 
prion strain in the original sheep AS isolates, and that AS prion strain replication in an ovine 134 
 7 
PrP host was accompanied by the generation of c-BSE prions. Collectively, these data provide 135 
compelling evidence for the emergence and the propagation of zoonotic mammalian prions 136 
during intra- and inter-host transmission of the AS prion strain.  137 
138 
 8 
Results  139 
A panel of 8 atypical scrapie (AS) cases collected from sheep and goats in five different 140 
European countries was obtained (Table1). All of the AS isolates displayed a multi-band 141 
abnormal PrP (PrP
res
) western blot profile that was considered to be specific for small 142 
ruminant AS (SI appendix Figure S1). This panel of AS isolates was transmitted to the VRQ 143 
ovine PrP transgenic mice (tg338). The transmission properties such as incubation period (SI 144 
appendix Table S1), vacuolar lesion profile (Figure 1a) and PrP
res
 western blot profile in the 145 
brain (SI appendix Figure S1), of the propagated AS isolates observed after two or three 146 
iterative passages in tg338 were similar and were the same as that previously reported for AS 147 
passage in tg338 mice (21-23).  148 
 149 
The panel of 8 AS isolates was individually serially transmitted (2 or 3 iterative passages) in 150 
bovine PrP transgenic mice (tgBov) (Table 1). On first passage, signs of clinical prion disease 151 
were observed in a low proportion of inoculated tgBov mice. PrP
res
 was detected by western 152 
blot in the brains of clinically affected mice and in some mice that displayed no apparent 153 
clinical signs of prion disease when euthanised at the end of their life expectancy. No PrP
res
 154 
accumulation was observed in tgBov mice after inoculation with several of the AS isolates 155 
(AS 2, AS 3, AS 5, AS 6 and AS 7), as was the case with classical scrapie PS42 (Table 1). 156 
 157 
Second passage of the AS isolates in tgBov mice was performed using either first passage 158 
PrP
res
-positive brains or pooled PrP
res
-negative brains as inoculum. During this process, 7 out 159 
of the 8 AS isolates caused the occurrence of clinical prion disease in a proportion of animals 160 
in each group inoculated. On third passage (available for AS 1, 2, 3, 4 and 7) 100% attack 161 
rates and mean incubation periods that ranged between 235 and 286 dpi were recorded (Table 162 
1). 163 
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At each passage stage, a three band PrP
res
 western blot profile characterised by a prominent 164 
di-glycosylated PrP band was observed in the brains of the clinically-positive tgBov mice 165 
(Figure 1b). Strikingly, the lesion profile (Figure 1a), the PrP
res
 western blot profile (Figure 166 
1b) and the histopathological lesions (Figure 1c) in the brains of AS inoculated tgBov mice 167 
were identical to those observed for transmission of c-BSE (sheep or cattle origin) to tgBov 168 
mice. Importantly, the inoculation of one classical scrapie isolate (PS42) to the same mouse 169 
models resulted in the occurrence of a 100% attack rate for prion disease with a short 170 
incubation period in tg338 mice (SI appendix Table S1), but no clinical disease or PrP
res
 171 
accumulation in the brains of tgBov (Table 1). 172 
 173 
In order to further characterize the nature of the TSE agent that propagated in tgBov mice 174 
inoculated with the AS isolates, prions obtained after second passage (isolate AS 2) or third 175 
passage (isolate AS 3) in this mouse line were transmitted (two iterative passages) to VRQ 176 
(tg338) and ARQ (tgARQ) ovine PrP transgenic mice (Table 2). The incubation periods 177 
(Table 2 and SI appendix Table S1), the lesion profile (Figure 2a) and the PrP
res
 western blot 178 
profile in the brain (Figure 2b) of tg338 mice inoculated with tgBov-adapted AS isolates 179 
clearly differed from those observed in the same mouse line inoculated with the original AS 180 
isolates.  181 
No PrP
res
 deposition could be detected in the spleen of tg338 mice inoculated with the original 182 
AS isolates (Figure 3a). Conversely, transmission in tg338 of tgBov-adapted AS isolates was 183 
associated with a PrP
res
 accumulation in the spleen as was transmission of ovine and cattle c-184 
BSE (Figure 3a). PrP
res
 WB profile in the spleen of tg338 mice that were inoculated with c-185 
BSE and AS isolates passaged in tgBov were identical (Figure 3b). 186 
Transmission of tgBov-adapted AS isolates in both tg338 and tgARQ mice resulted in prion 187 
incubation periods (Table 2), brain vacuolar lesion profiles (Figure 2a), PrP
res
 western blot 188 
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profile patterns (Figure 2b) and PrP
res
 distribution patterns in the brain (Figure 3a) that were 189 
similar to c-BSE passaged in tg338 and tgARQ mice. Collectively these results demonstrate 190 
beyond reasonable doubt that our transmission of AS in a bovine PrP host resulted in the 191 
propagation of the c-BSE agent. Since the bioassays reported here were performed in three 192 
independent institutes (located in France and Spain) that used inoculum prepared by five 193 
distinct laboratories, we exclude the possibility of a cross contamination of the original AS 194 
isolates by the c-BSE agent. 195 
 196 
Two hypotheses could explain the emergence of the c-BSE agent in tgBov mice after their 197 
inoculation with AS isolates. Firstly, c-BSE prions could be present at a low level in the 198 
original AS isolates. The high sensitivity of tgBov mice for detection of the c-BSE agent 199 
could allow this potentially low level of bovine prions to be identified during passage of the 200 
original AS isolates in the bovine PrP host. Alternatively, the occurrence of c-BSE in AS-201 
inoculated tgBov mice could result from a mutation of AS strain properties triggered by 202 
passage across the bovine transmission barrier for this particular ovine prion strain.  203 
 204 
In order to explore the origin of the c-BSE agent observed in tgBov mice inoculated with AS, 205 
we employed in vitro protein misfolding cyclic amplification (PMCA), a methodology that 206 
mimics prion replication in vitro, but in an accelerated form, allowing amplification of minute 207 
amounts of PrP
Sc
 and prion infectivity (27). In PMCA, a PrP
C
-containing substrate is 208 
combined with a seed that contains PrP
Sc
. Following repeated cycles of incubation and 209 




PMCA has been previously reported to amplify the c-BSE agent with a great efficacy using 212 
either tgARQ or tgBov mouse brain homogenate as substrate (28). Using this protocol two 213 
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(tgARQ substrate) or three (tgBov substrate) amplification rounds were sufficient to reach the 214 
detection limit for c-BSE prion seeding activity (SI appendix Figure S2). The level of prion 215 
infectivity and prion seeding activity of a reference sheep-passaged c-BSE isolate were end-216 
point titrated by both bioassay in tgBov mice and PMCA, respectively (SI appendix Table 217 
S2). The infectious prion titer of the sheep-passaged c-BSE isolate was ≈10
7.2
 LD50/g IC in 218 
tgBov mice. The prion seeding titer (SA50) was estimated to be ≈10
11.1
 SA50/g using tgARQ 219 
mouse tissue as substrate and 10
11.05
 SA50/g using tgBov mouse tissue as substrate. 220 
Considering the fact that mice were inoculated using 20µL of sample and the PMCA reactions 221 
were seeded using 5µL of the same sample, the PMCA can be considered to be about 1500 222 
fold more sensitive than the bioassay in tgBov. This also means that 1 c-BSE LD50 in tgBov 223 
mice corresponds to ≈1500 SA50 assessed by PMCA.  224 
 225 
In addition to its high sensitivity, in vitro PMCA can reproduce, at least partly, the 226 
transmission barrier phenomenon observed during the in vivo prion bioassay (29). Therefore, 227 
amplification of prion seeding activity in AS isolates by PMCA using tgBov mouse tissue as 228 
substrate offered an opportunity to characterize the potential impact of the bovine 229 
transmission barrier on AS strain properties.   230 
 231 
The AS isolates that were originally transmitted to tgBov mice (except AS8) and 18 additional 232 
AS isolates (originating from Norway, France, and Portugal) were subjected to PMCA (Table 233 
4). Each AS isolate was used to seed reactions containing either bovine PrP or ovine ARQ PrP 234 
substrate (10 to 18 replicates per substrate). After amplification, PrP
res
 was detected by 235 
western blot in a low proportion of the reactions seeded with 19 out of the 25 AS isolates for 236 
tgBov and tgARQ combined (Table 3). In most instances, a similar proportion of PrP
res
-237 
positive PMCA reactions were observed when either bovine PrP or ovine ARQ PrP was used 238 
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as substrate. However, in some cases (n=3), a low number of PrP
res
-positive reactions were 239 
observed when bovine PrP was used as substrate (in the case of AS 10) or when ovine ARQ 240 
PrP was used as substrate (in the case of AS 9, and AS 25). Whatever combination of AS 241 
isolate and substrate PrP used, the PrP
res
 western blot profile in PMCA-positive reaction 242 
products and its reactivity with 12B2 antibody were indistinguishable from those observed for 243 
PMCA reaction products seeded with authentic ovine c-BSE prions (Figure 4). No PrP
res
 was 244 
observed in PMCA reactions that were unseeded (n=120) or in those reactions seeded (n=60) 245 
with prion-free sheep brain homogenate (representative samples shown in Figure 4). It should 246 
be noted that the PrP amino sequence was 100% homologous between certain AS isolates (AS 247 
5, AS 26) and the ovine PrP substrate (tgARQ) used in PMCA reactions. Therefore, in vitro 248 
amplification of c-BSE prions in PMCA reactions seeded with these AS isolates using ovine 249 
ARQ PrP as substrate cannot be a consequence of mutation of prion strain properties triggered 250 
by a transmission barrier. 251 
 252 
Taken together, the tgBov mouse bioassay and PMCA results strongly support the view that a 253 
low level of c-BSE prions was initially present in at least 21 out of the 26 AS isolates tested.  254 
 255 
To further clarify the origin of the c-BSE agent detected in AS isolates, two of these isolates 256 
(AS 25 and AS 26) were end-point titrated in tg338 mice (1/10 dilution series, 6 to 7 tg338 257 
mice inoculated per dilution). For both isolates, the last positive transmissions were observed 258 
in mice that received a 10
-6
 log10 dilution of the original 10% w/vol brain material (SI 259 
appendix Table S3). The brains of these end-point titration tg338 mice were subsequently 260 
subjected to PMCA. Irrespective of the substrate used for PMCA, either bovine or ovine ARQ 261 
PrP, PrP
res
 was observed in a similar proportion of the PMCA reactions seeded with either the 262 
original AS isolates, or AS isolates passaged in tg338 mice (Table 4). The PrP
res
 western blot 263 
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profile observed in all the PMCA-positive reactions was identical to that seen in reactions 264 
seeded with authentic c-BSE prions (Figure 5). PMCA reactions seeded with brain 265 
homogenate prepared from age matched non-inoculated tg338 mice remained PrP
res
 negative 266 
(Table 4 and Figure 5).  267 
 268 
Considering the level of c-BSE seeding activity originally present in isolates AS 25 and AS 269 
26 (less than 100 SA50/mL, Table 5), there is an extremely low level of probability that one of 270 
the six tg338 mice inoculated with 20µL of a 10
-6
 diluted AS isolate (<2 10
-6
 SA50 per dose of 271 
inoculum) could be exposed to 1 infectious dose of c-BSE agent (1 c-BSE LD50 is ≈1500 272 
SA50). Consequently, the presence of c-BSE prion seeding activity in the brains of tg338 mice 273 
inoculated with a 10
-6
 log10 dilution of original AS isolate implies that a low titer of c-BSE 274 
prions was generated during the propagation of ovine AS prions in a host that expressed ovine 275 





The mechanism(s) that lead to an alteration in the phenotype of prion strains as these 280 
transmissible entities undergo transmission between different host species remain uncertain. 281 





, together with prion strain identity are principal determinants of the 283 
transmission barrier (9, 10). Based on the concept that conformation of PrP
Sc
 284 
molecules/aggregates encode prion strain information (2, 4, 5, 30, 31), at least two non-285 
exclusive hypotheses, ‘deformed templating’ (32, 33) and the ‘conformational selection 286 
model’ (32-35) have been proposed to explain the mutation of prion strains. 287 
 288 
The ‘deformed templating’ hypothesis postulates that a prion strain replicates as a clone of 289 
PrP
Sc
 molecules/aggregates. When confronted by a transmission barrier that does not allow 290 
clonal prion replication, the propagation process is modified so that ‘altered’ PrP
Sc
 structural 291 
variants are generated in an attempt to convert the new host PrP
C
. While the majority of these 292 
presumably fail to replicate efficiently in the new host, variants eventually emerge that are 293 
successful and adapt to the new PrP environment through multiple trial-and-error replication 294 
events. In this ‘deformed templating’ model, confrontation of the transmission barrier serves 295 
as the triggering event that initiates the generation of new prion variant(s) and as a filter for 296 
their selection (35). 297 
 298 
The ‘conformational selection model’ proposes that a prion strain naturally propagates in its 299 
host as an ensemble of PrP
Sc
 conformers dominated by a stable energetically favourable 300 
conformation responsible for the observed prion strain phenotype. Furthermore, this model 301 
predicts that the number of stable PrP
Sc
 conformers is limited for each PrP amino acid 302 
sequence, which would explain the existence of a finite number of stable prion strains that can 303 
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propagate in a given species. It is further proposed that during transmission of a prion strain to 304 
a new host, one of the less dominant PrP
Sc
 conformers of those present in the ensemble is 305 
selected with a resultant change, or mutation, in the properties of the newly propagating prion 306 
strain. In the ‘conformational selection model’, the transmission barrier acts simply as a 307 
selective filter for new prion variants, and ease of permeation of the barrier results from the 308 
extent of overlap of PrP
Sc
 conformers that exist between the interacting species (32, 33).  309 
 310 
Our data reported here showed that c-BSE prions are present as a minor variant in natural 311 
isolates of ovine AS. In addition, transmission of ovine AS to bovine PrP mice demonstrated 312 
that c-BSE can emerge during these transmissions as the dominant prion strain. These results 313 
provide a cogent argument in favour of the ‘conformational selection model’ as the 314 
mechanism for prion strain mutation during inter-species prion transmission. This would be 315 
expected to occur by selection of a pre-existing PrP
Sc
 variant in AS isolates, one best suited to 316 
the new replicative environment. Within this conceptual framework, the occurrence of prion 317 
strain mutation is dependent upon the particular repertoire of PrP
Sc
 variants associated with 318 
distinct prion strains. This notion is supported by our observation that c-BSE prions emerged 319 
during serial transmission of ovine AS in tgBov mice but not from serial passage of classical 320 
scrapie in the same mouse line (Table 1 and Cassard et al (15)).  321 
 322 
The diversity of prion strains that exist in small ruminants remains undefined although it is 323 
established that at least 5 different natural ovine prion strains exist including AS (6, 36-39). 324 
According to the ‘conformational selection model’, each of these different ovine prion strains 325 
is associated with a unique and stable PrP
Sc
 conformer and a distinct set of minor variants. 326 
The tgBov mouse line has previously been reported to support the propagation of a variety of 327 
natural ovine prions, of which several displayed significantly shorter incubation periods than 328 
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c-BSE (15). Strikingly, in our experiments the diversity of prion variants in the AS isolates 329 
(seven different cases) revealed by the serial passage in tgBov was restricted to the c-BSE 330 
agent (Table 1). This consistent emergence of a single prion strain argues against the view that 331 
AS prion replication in sheep can randomly generate all the existing stable PrP
Sc
 variants 332 
associated with a particular ovine PrP
C
 amino acid sequence. Instead, our data support the 333 
view that individual prion strains are associated with a restricted repertoire of stable PrP
Sc
 334 
variants in a given host.  Whether AS is unique in its ability to generate c-BSE prion particles 335 
during its replication process remains to be established. 336 
 337 
Classical BSE was first recognized in 1984-85 as a novel prion disease affecting cattle in the 338 
UK (40). Epidemiological data clearly established that the number of cases of c-BSE was 339 
amplified by the recycling of infected animal carcasses into cattle feed in the form of meat 340 
and bone meal (MBM) (41). Since bovine prion disease had not been recognized in cattle 341 
prior to the c-BSE epizootic and the disease is apparently non-contagious between cattle, 342 
several hypotheses were proposed to explain its emergence. These range from the spontaneous 343 
occurrence of c-BSE in cattle to the passage and adaptation of a prion originating from 344 
another species (42, 43). Our studies here that show the presence of c-BSE prions in AS 345 
isolates combined with the demonstrated presence of AS in the UK long before the 346 
appearance of the c-BSE epizootic in cattle suggests that the recycling of AS cases in MBM 347 
might be a source of bovine prion disease (20).  In addition to its potential role in the initial 348 
emergence of c-BSE in cattle, the presence of c-BSE prions in natural cases of AS has current 349 
and direct implications for both the continued risk of this ovine prion disease to other farmed 350 
animals and for human exposure risks. The distribution of AS cases are widespread across the 351 
world (17-19). A recent retrospective analysis of surveillance data collected over a period 352 
exceeding 10 years in the European Union (EU) concluded that the prevalence of detected AS 353 
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cases has remained relatively stable in the different member states with between 2-6 positive 354 
cases per 10,000 tested animals per year. This implies that a substantial number of AS-355 
infected animals could enter either the animal or human food chain each year (44, 45), and 356 
each case represents a potential source of exposure to the c-BSE agent for farmed animals 357 
(MBM derived from rendered small ruminants) and human consumers (consumption of 358 
healthy slaughtered animals), respectively. The epidemiological features of AS within the EU 359 
is likely to reflect the situation of the disease in other countries that breed and maintain small 360 
ruminants.  361 
 362 
In Europe, the c-BSE crisis and the emergence of vCJD resulted in the implementation of a 363 
strong and coherent policy (EU regulation 999/2001) aimed at control and eradication of this 364 
animal prion disease. The total feed ban on the use of MBM in animal feed and the systematic 365 
retrieval from the food chain of ruminant tissues that have the potential to contain high levels 366 
of prion infectivity, so called Specified Risk Material (SRM) measures, were instrumental for 367 
control of c-BSE in cattle and preventing dietary human exposure to these bovine prions (46, 368 
47). As a side effect, these measures also strongly limited the exposure of farmed animals and 369 
human consumers to the other TSE agents circulating in farmed animal species, including AS.  370 
 371 
With the decline of the c-BSE epizootic in cattle and the combined increase in pressure from 372 
industry, EU authorities have begun to consider discontinuing certain TSE control measures. 373 
The abrogation of the SRM measures for small ruminants and the partial re-authorization of 374 
the use of processed animal protein, formerly known as MBM in animal feed are part of the 375 
EU authorities’ agenda. Our observation of the presence of the c-BSE agent in AS-infected 376 
small ruminants suggest that modification of the TSE control measures could result in an 377 
increased risk of exposure to c-BSE prions for both animals and humans. Whether or not this 378 
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exposure will result in further c-BSE transmission in cattle and/or humans remains an open 379 





Ethics Statement 384 
All animal experiments were performed in compliance with institutional and French national 385 
guidelines and in accordance with the European Directives 86/609/EEC and 2010/63/EU. In 386 
France, the animal experiments that are part of this study (national registration 01734.01) 387 
were approved by the local ENVT ethics committee. Experiments developed in CISA-INIA 388 
(Madrid, Spain) were approved by the Committee on the Ethics of Animal Experiments of the 389 
Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria and the General 390 
Directorate of the Madrid Community Government (permit numbers: CEEA 2009/004 and 391 
PROEX 228-16). Mouse inoculations were performed under anaesthesia (isofluorane).  392 
Experiments  developed in IRTA-CReSA (Barcelona, Catalonia) involving animals were 393 
approved by the animal experimentation ethics committee of the Autonomous University of 394 
Barcelona (Reference number: 585-3487) in agreement with Article 28, sections a), b), c) and 395 
d) of the “Real Decreto 214/1997 de 30 de Julio” and the European Directive 86/609/CEE and 396 
the European council Guidelines included in the European Convention for the Protection of 397 
Vertebrate Animals used for Experimental and Other Scientific Purposes.  398 
Mice that displayed clinical signs were anesthetized with isofluorane before sacrifice using 399 
CO2 inhalation. 400 
 401 
Atypical/Nor98 scrapie cases and control sheep  402 
Natural atypical scrapie (AS) cases identified through active or passive surveillance programs 403 
were selected according to their geographical origin (France, Spain, Italy, Norway and 404 
Portugal) and PRNP genotypes (SI appendix Table S1 and Table 1). These cases have been 405 
originally classified as AS by TSE national reference laboratories in each country. All the 406 
cases corresponded to sheep except the AS 7 case (goat). 407 
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 408 
In all cases, PrP genotype was checked by sequencing the Exon 3 of the PRNP gene as 409 
previously described (48). The polymorphisms at codons 136 (A/V), 154 (H/R) and 171 410 
(R/Q/H), which have been demonstrated to strongly influence the susceptibility to TSE in 411 
sheep are indicated (49). Additionally, the presence of a phenylalanine at codon 141 (F/L), 412 
which has been shown to impact on the susceptibility to atypical/Nor98 scrapie, are also 413 
indicated (Table 1 and 4) (23, 48). Brain material collected in TSE-free Poll-Dorset sheep 414 
(APHA, Weybridge, UK) was used as control (50).  415 
 416 
c-BSE isolates 417 
Cattle and ovine classical BSE (c-BSE) isolates were used as control. The cattle c-BSE isolate 418 
was a natural case originating from France. This isolate was used in previous studies aimed at 419 
the characterization of c-BSE strain properties though transmission to mice over-expressing 420 
the PrP sequence of various host species (51). The  ovine c-BSE isolate was obtained by the 421 
intracerebral inoculation of the same cattle c-BSE isolate in ARQ/ARQ TSE free sheep (first 422 
passage) as described in Andreoletti et al 2004 (50).  423 
 424 
Mouse bioassays 425 
Bioassays were carried out using mice expressing bovine PrP (tgBov /tg110) (52, 53) and/or 426 
mice expressing ovine ARQ (tgARQ) (54) or VRQ (tg338) PrP (55).  427 
 428 
Groups of six- to ten-week-old female mice (n ≥6) were anesthetized and inoculated with 429 
20µL of a 10% tissue homogenate in the right parietal lobe using a 25-gauge disposable 430 
hypodermic needle. Mice were observed daily and their neurological status was assessed 431 
weekly. When clinically progressive TSE disease was evident, the animals were euthanized 432 
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and their brains harvested. Half of the brain was fixed by immersion in 10% formol saline and 433 
the other half was frozen at -20ºC. Tissues from animals found dead were frozen (no formalin 434 
fixation). In animals where no clinical signs were observed, mice were killed at the end of 435 
their natural life-span (650 to 750 days). In those cases, incubation periods reported in the 436 
table as >650 dpi, corresponded to the survival time observed in at least three out of the six 437 
mice.  438 
 439 
PMCA Amplification 440 
Brains from tgBov, tgARQ and tg338 were used to prepare the PMCA substrates. PMCA was 441 
performed as previously described (28, 56). Briefly PMCA reactions (50µL final volume) 442 
were seeded with 5µL of sample to be tested. PMCA reactions were then subjected to 3 443 
amplification rounds each comprising 96 cycles (10s sonication-14 minutes and 50 seconds 444 
incubation at 39.5°C) in a Qsonica700. After each round, reaction products (1 volume) were 445 
mixed with fresh substrate (9 volumes) to seed the following round. The PMCA reaction 446 
products were analysed by western blot for the presence of PK-resistant PrP. Each WB line 447 
was loaded with the equivalent of 20 µL of PK digested PMCA product. Each PMCA run 448 
included a reference ovine BSE sample (10% brain homogenate) as a control for the 449 
amplification efficiency. Unseeded controls (2 unseeded controls for 8 seeded reactions) were 450 
also included in each run. 451 
 452 
Western blot detection of abnormal PrP 453 
PK-resistant abnormal PrP (PrP
res
) extraction and western blot were performed as previously 454 
described (57). Immunodetection was performed using two different PrP-specific monoclonal 455 
antibodies: Sha31 (1 µg/ml) (58), and 12B2 (4 µg/ml) (59), which recognize the amino acid 456 




Paraffin embedded tissue blot  460 
Paraffin embedded brain tissue from inoculated mice was analysed as previously described 461 
(61-63). 462 
 463 
Lesion profiling and abnormal PrP immunohistochemistry. 464 
Vacuolar brain lesion profiles were established following the method described by Fraser et al 465 
(64). In situ PrP
Sc
 immune-labelling was performed as previously described (63), using 6H4 466 
anti PrP antibody (epitope: 147DYEDRYYRE155 of the bovine PrP- concentyrtation 3µg/mL).  467 
 468 
Infectious and seeding activity titer estimates 469 
A series of 1/10 dilutions of a reference 10% w/vol brain stem from an ovine-BSE 470 
(ARQ/ARQ) isolate and two AS isolates (AS 25 and AS 26) were prepared. Successive 1/10 471 
dilutions of brain homogenate were inoculated intra-cerebrally (20µl) into tgBov or tg338 472 
mice (n=6 per inoculum). Dilutions of the same c-BSE isolate were used to seed PMCA 473 
reactions that used brain tissue from either bovine PrP (tgBov mice) or ovine ARQ PrP 474 
(tgARQ mice) as substrate. Twelve individual replicates of each sample dilution were tested. 475 
Reactions were then subjected to three amplification rounds. PMCA reaction products (third 476 
amplification round) were analysed by western blot for the presence of PrP
res
. The titer of 477 
prion seeding activity was estimated by the Spearman-Kärber’s method (65). 478 
 479 
For AS and AS passaged in tg338 isolates (10% brain homogenate), 1/50 diluted material was 480 
used to seed twelve individual reactions (tgBov or tgARQ substrates). After three 481 
amplification rounds the number of PrP
res
 western blot positive reactions / total number of 482 
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reactions was established. These ratios were used to estimate seeding activity titers (SA/µL of 483 
10% brain homogenate) by the limiting dilution titration method (application of Poisson’s 484 
probabilistic model) described by Brown et al (66) or by the Spearman-Kärber’s method. 485 
According to Fisher et al (67) and as previously used for prion infectivity comparisons (68) 486 
one SA50 was considered to be equivalent to 0.693 SA. 487 
 488 
Data availability 489 
 490 
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Legends of Figures 660 
 661 
Figure 1: Brain lesion profile and PrP
res
 western blot profiles in tgBov and tg338 mice 662 
inoculated with atypical/Nor98 scrapie (AS) or c-BSE  663 
 664 
Groups of mice (n≥6) that express either ovine VRQ PrP (tg338 mice) or bovine PrP (tgBov 665 
mice) were intra-cerebrally challenged with atypical scrapie isolates (AS) or an ovine classical 666 
BSE isolate (c-BSE). 667 
(a) After two or three iterative passages in each mouse line a standard lesion profile was 668 
established by scoring the vacuolar changes observed in pre-defined brain areas. In c-BSE 669 
graphs : ovine c-BSE, : cattle c-BSE. In AS graphs:  : AS 1, : AS 2, : AS 3). 670 
(b) The accumulation of PK-resistant PrP (PrP
res
) in the brain of tgBov mice was established 671 
by western blot using anti PrP monoclonal antibodies Sha31 (epitope 145-YEDRYYRE-152) 672 
and/or 12B2 (epitope 89-WGQGG-93). The same western blot PrP
res
 control (classical scrapie 673 
isolate) was used on all the gels labelled as WB control. Cattle c-BSE and an ovine c-BSE 674 
(original isolate and isolate passaged in tgBov) were included as controls. 675 
(c) Vacuolar lesions (thalamus level, conventional histology; hematoxylin-eosin, bar: 25 µm) 676 
and abnormal PrP deposition (Mesencephalon: tegmentum, immunohistochemistry using 6H4 677 
anti PrP antibody, epitope 147-DYEDRYYRE-155, bar: 50µm) in tgBov mice inoculated with 678 
AS3 and cattle BSE. 679 
 680 
 681 
Figure 2: Brain lesion profile and PrP
res
 Western blot in the brain of tgARQ and tg338 682 
mice inoculated with AS scrapie adapted in tgBov 683 
 684 
Groups of mice (n≥6) that express ovine VRQ PrP (tg338 mice) or ovine ARQ PrP (tgARQ 685 
mice) were intra-cerebrally challenged with atypical scrapie isolates (AS) or an ovine c-BSE 686 
isolate that had previously been adapted (2 iterative passages) in tgBov mice.  687 
(a) After two iterative passages in each mouse line a standard lesion profile was established 688 
by scoring the vacuolar changes observed in pre-defined brain areas. In AS graphs : AS 2, 689 
: AS 3. 690 
(b) The western blot profile of PK resistant PrP (PrP
res
) in the original AS isolates and in the 691 
brain of inoculated mice was established by western blot using anti PrP monoclonal antibody 692 
Sha31 (epitope 145-YEDRYYRE-152). The same western blot PrP
res
 control (classical 693 
scrapie isolate) was used on all the gels labelled as WB control. 694 
 695 
Figure 3: Brain and spleen PrP
res
 accumulation in tg338 mice inoculated with AS scrapie 696 
adapted in tgBov 697 
 698 
Groups of mice (n≥6) that express ovine VRQ PrP (tg338 mice) were intra-cerebrally 699 
challenged with atypical scrapie isolates (AS) and AS that had previously been adapted (2 700 
iterative passages) in tgBov mice. In parallel, cattle c-BSE isolate and ovine BSE isolate 701 
(adapted in tg Bov) were transmitted (2 iterative passages) in tg338 mice. 702 
(a) In tg338 mice (2
nd
 passage) the PrP
res
 distribution pattern in the brain (thalamic coronal 703 
section: bar: 160 µm) and in the spleen (bar: 100 µm) was established by paraffin embedded 704 
tissue blot using anti PrP monoclonal antibody Sha31 (epitope 145-YEDRYYRE-152). 705 
(b) The western blot profile of PK resistant PrP (PrP
res
) in the spleen of tg338 mice (2
nd
 706 
passage) inoculated with AS isolates, AS isolates passaged in tgBov and c-BSE (cattle and 707 






 detection in PMCA reactions seeded with atypical/Nor98 scrapie 711 
isolates. 712 
 713 
Protein misfolding cyclic amplification (PMCA) reactions were seeded with Atypical/Nor98 714 
scrapie (AS) isolates (1/50 diluted 10% brain homogenate) that had been identified in five 715 
European countries (see Table 3). PMCA reactions seeded with brain homogenate from a 716 
TSE-free sheep (originating from New Zealand) and unseeded PMCA reactions were included 717 
as specificity controls. PMCA substrate consisted of brain homogenate from either bovine PrP 718 
(tgBov) or ovine PrP (tgARQ) mice. PMCA reactions were subjected to three (tgARQ 719 
substrate) or four (tgBov substrate) amplification rounds each comprising 96 cycles (10s 720 
sonication-14 minutes and 50 seconds incubation at 39.5°C) in a Qsonica700. The PMCA 721 
reactions were analysed by western blot for the presence of abnormal PK-resistant PrP (PrP
res
) 722 
using anti PrP monoclonal antibodies Sha31 (epitope 145-YEDRYYRE-152) and/or 12B2 723 
(epitope 89-WGQGG-93). Each western blot included a classical scrapie isolate (labelled as 724 
WB control) and an ovine c-BSE isolate as controls. 725 
 726 
Figure 5: PMCA seeding activity detection in two bioassay end-point titrated 727 
Atypical/Nor98 isolates  728 
 729 
Two atypical/Nor98 isolates AS 25 and AS 26 (Table 3) were end-point titrated in tg338 mice 730 
(1/10 dilution series, 6 tg338 mice per dilution). For both isolates, the last positive 731 
transmissions were observed in mice that received a 10
-6
 dilution of the original 10% w/vol 732 
brain material (SI appendix Table S3). The original AS isolates and the brains of clinically 733 
affected mice inoculated with neat and 10
-6
 diluted isolates were used to seed PMCA reactions 734 
that either used tgARQ or tgBov as substrate. PMCA reactions seeded with age matched 735 
inoculated tg338 mice and unseeded reactions were included as specificity controls. Reactions 736 
were subjected to three (tgARQ substrate) or four (tgBov substrate) amplification rounds each 737 
comprising 96 cycles (10s sonication-14 minutes and 50 seconds incubation at 39.5°C) in a 738 
Qsonica700. The PMCA reactions were analysed by western blot for the presence of 739 
abnormal PK resistant PrP (PrP
res
) using the Sha31 (epitope 145-YEDRYYRE-152) and/or 740 
the 12B2 (89-WGQGG-93) anti PrP antibodies. Each western blot included a classical scrapie 741 
isolate (labelled as WB control) and an ovine c-BSE isolate as controls. 742 
 743 
 744 
Table 1: Inoculation of atypical scrapie isolates in bovine PrP (tgBov) expressing mice  
Isolates  TgBov 
    1st passage  2nd passage  3rd passage 











            
AS 1 Fr ARQ*/ARQ  1/6 533  3/5 317±63  7/7 235±16 
            
AS 2 Sp ARR/ARQ  0/6 >650  7/9 354±26  5/5 273±5 
            
AS 3 Sp ARQ/ARH  0/6 >650  2/11 504, 525‡  12/12 269±13 
            
AS 4 Nor ARQ*/ARQ*  3/4 395± 44  6/6 230±17   6/6 271±18 
      
AS 5 Sp ARQ/ARQ  0/6 >650  0/4 >650  NA  
      
AS 6 Sp ARQ/ARH  0/6 >650  1/4 >650‡   NA  
            
AS 7† It ARQ/AHQ   0/6 >650  1/7 424  6/6 286±14 
            
AS 8 Po ARQ/ARQ  1/5 439  5/5 297±14  6/6 250±4 
      
PS42 Fr VRQ/VRQ  0/6 >650  0/6 >650  0/6 >650 
      
Ovine c-
BSE Fr ARQ/ARQ  6/6 254±19  6/6 234±12  6/6 232±6 
            
Cattle c-
BSE Fr -  6/6 295±12  6/6 265±35  6/6 243±7 
      
Transgenic mice that express the bovine PrP (tgBov) were inoculated intra-cerebrally (6 to 12 mice, 20µL per 
mouse) with 8 sheep or goat (†) atypical scrapie (AS) isolates originating from five different countries; France 
(Fr), Spain (Sp), Norway (Nor), Italy (It) or Portugal (Po). The AS affected animals displayed a different PRNP 
genotype at codons 136, 154 and 171. Some also displayed a F/L dimorphism at codon 141 (*). Cattle classical 
BSE (c-BSE), ovine c-BSE (first passage of cattle c-BSE in an ARQ/ARQ sheep by the intracerebral route) and 
classical scrapie (PS42) isolates were inoculated in the same mouse model. After first and second passage, 
clinically affected or asymptomatic mice that had lived for more than 500 days post inoculation were pooled and 
used for subsequent passage in the same line. Mice were considered positive when abnormal PrP deposition was 
detected in the brain. (‡) indicate abnormal PrP positive and found dead animals (without symptoms). Incubation 
periods (in days) are shown as mean±SD except when less than 50% of the mice were found to be positive. In 
that case the incubation periods of the positive mice are individually presented. NA: not available. Cattle c-BSE 
transmission in tgBov data were already reported in Torres et al 2014 (51) 
  
Table 2: Inoculation of atypical scrapie adapted in tgBov and c-BSE isolates in ovine PrP 
expressing mouse models (tg338 and tgARQ) 
   Tg338  TgARQ 
Isolates  1st passage  2nd passage  1st passage  2nd passage 















              
AS 2 2
nd pass in 
TgBov  6/6
‡ >650  6/6 617±75  6/6 350±9  6/6 260±3 
       
AS 3 3
rd pass in 
TgBov   6/6
‡ >650  6/6 672±83  6/6 354±21  6/6 257±2 
              
Ovine c-
BSE 
2nd pass in 
TgBov  6/6
‡ >750  6/6 653±32  6/6 270±12  6/6 259±4 
       
Cattle c-
BSE cattle  6/6
‡ >700  6/6 682±52  6/6 321±16  6/6 263±7 
              
 
Transgenic mice that express the VRQ (tg338) or ARQ (tgARQ) variants of ovine PrP were inoculated intra-
cerebrally (6 mice, 20µL per mouse) with atypical scrapie isolates or ovine c-BSE isolate that had previously 
been adapted in tgBov (2 iterative passages). Cattle BSE was also included as control. After first passage, 
clinically affected or asymptomatic mice that had lived for more than 500 days post inoculation were pooled and 
used for second passage in the same line. Mice were considered positive when abnormal PrP deposition was 
detected in the brain. (‡) indicate abnormal PrP positive and found dead animals (without symptoms). Incubation 
periods (in days) are shown as mean±SD.  
 
  
Table 3: Protein Misfolding Cyclic Amplification seeding activity in atypical scrapie isolates 
Isolates  PMCA positive reactions 
Identifiant Origin Genotype   TgBov substrate  
TgARQ 
substrate 
       
AS 1 Fr ARQ*/ARQ  3/12  5/12 
AS 2 Sp ARR/ARQ  2/12  3/12 
AS 3 Sp ARQ/ARH  3/12  4/18 
AS 4 No ARQ*/AFRQ  12/12  9/12 
AS 5 Sp ARQ/ARQ  4/12  3/12 
AS 6 Sp ARQ/ARH  5/12  1/12 
AS 7 It ARQ/AHQ  1/12  2/12 
AS 8 Po ARQ/ARQ  ND  ND 
       
AS 9 Nor ARR/ARQ 0/12  2/10 
AS 10  ARQ*/AHQ  1/12  0/10 
AS 11  AHQ/ARQ  3/12  7/12 
AS 12  ARR/ARQ  0/12  0/12 
AS 13  ARR/AHQ  0/12  0/12 
AS 14  ARQ/AHQ  1/12  1/12 
AS 15  ARR/ARR  3/12  1/12 
AS 16  ARR/AHQ  1/12  3/10 
AS 17  ARQ*/AHQ  1/12  1/10 
AS 18  ARQ*/AHQ  0/12  0/10 
       
AS 19 Po ARR/ARR 0/12  0/12 
AS 20  ARR/AHQ  3/12  1/12 
AS 21  ARR/ARR  0/12  0/10 
AS 22  ARQ*/AHQ  0/12  0/12 
AS 23  ARQ*/ARQ  1/12  1/12 
AS 24  ARQ*/ARQ  2/12  4/12 
      
AS 25 Fr AHQ/AHQ  0/12  1/12 
AS 26  ARQ/ARQ  1/12  1/12 
       
TSE free sheep  ARQ/ARQ  0/12  0/12 
       
Unseeded  -  0/120  0/120 
       
 
Twenty-six AS scrapie cases (1/50 diluted 10% brain homogenates) originating from five different countries 
(France (Fr), Spain (Sp), Italy (It), Portugal (Po) and Norway (Nor)) were used to seed PMCA reactions (5 µl of 
seed per reaction). The AS affected animals displayed different Prnp genotypes at codons 136, 154 and 171. 
Some also displayed a F/L dimorphism at codon 141 (*).  
Two different PMCA substrates were used. The first one was prepared using brains from transgenic mice over-
expressing the ARQ variant of the sheep prion protein (tgARQ). The second was prepared using brains from 
transgenic mice over-expressing the bovine prion protein (tgBov). For each isolate and substrate ten to eighteen 
individual replicates were tested. Reactions were subjected to 3 amplification rounds. After each round reaction 
products (1 volume) were mixed with fresh substrate (9 volumes) to seed the following round. PMCA reaction 
products (third amplification round) were analysed by western blot for the presence of PrPres. The number of 
PrPres western blot positive reactions / total number of reactions are reported. Unseeded reactions and reactions 
seeded with brain homogenate prepared from a TSE free sheep were included as specificity controls. ND: not 
done. 
Table 4: PMCA seeding activity in atypical scrapie passaged in tg338 
PMCA seeds PrP
res positive 
PMCA reactions  
Seeding activity  
(SA50/mL) 




substrate   
TgARQ  
substrate 
          
AS 25 Sheep   0/12 1/12  0 (0-101.86)*  101.40
 1st passage in tg338 (neat) Mouse 1  2/12 1/12  101.72  10
1.40
 2nd passage in tg338 (neat) Mouse 1  2/12 1/12  101.72  101.40
 End-point titration in tg338 (10-6 dilution) Mouse 1  2/12 3/12  
101.72  101.92 
  Mouse 2  1/12 3/12  101.40  101.92 
  Mouse 3  2/12 2/12  101.72  101.72 
          
AS 26 Sheep   1/12 1/12  101.40  101.40 
 1st passage in tg338 (neat) Mouse 1  2/12 0/12  101.72  0 (0-101.86) * 
 2nd passage in tg338 (neat) Mouse 1  2/12 0/12  101.72  0 (0-101.86) * 
 End-point titration in tg338 (10-6 dilution) Mouse 1  2/12 1/12  10
1.72  10
1.40
  Mouse 2  1/12 1/12  101.40  101.40
          
 Non inoculated tg338  Mouse 1  0/12 0/12  -  - 
  Mouse 2  0/12 0/12 - -
  Mouse 3  0/12 0/12  -  - 
          
Two sheep atypical scrapie (AS) isolates were selected. The 10% w/vol brain homogenates were inoculated into 
tg338 mice (2 iterative passages). Groups of 6 tg338 mice were inoculated intra-cerebrally with 20µL of serial 
ten-fold dilutions of the same homogenates. Transmission was observed in 3 (AS 25) and 2 (AS 26) mice 
inoculated with 10-6 brain homogenate. No transmission was observed at lower dilutions. PMCA reactions (12 
replicates) were seeded with 1/50 diluted brain homogenate (10% w/vol) from (i) the original sheep, (ii) the 
second passage tg338 mice (pool of brains) and (iii) individual brain from positive tg338 in the end-point 
titration experiment. Brain homogenates (10% w/vol) from age matched, non-inoculated tg338 mice were also 
used as seeds (1/50 diluted). Two different PMCA substrates were used. The first one was prepared using brains 
from transgenic mice over-expressing the ARQ variant of the sheep prion protein. The second was prepared 
using brains from transgenic mice over-expressing the bovine prion protein (tgBov). Reactions were subjected to 
up to 4 amplification rounds. After each round reaction products (1 volume) were mixed with fresh substrate (9 
volumes) to seed the following round. PMCA reaction products were analysed by western blot for the presence 
of PrPres. The number of PrPres western blot positive reactions / total number of reactions are reported. Seeding 
activity titers were estimated using the Spearman Karber’s limiting dilution titration method (most likely value) 
or when no positive reaction was observed, by the Poisson’s probabilistic model (*: most likely value and IC 
95%) as described by Brown et al (66). Titers are given as the number of PMCA SA50 per mL of 10% brain 
homogenate. 





